The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
London, GB
Size (employees)
38 (est)+9%
Synthace was founded in 2011 and is headquartered in London, GB
Report incorrect company information

Key People/Management at Synthace

Tim Fell

Tim Fell

Christopher Grant Ward

Christopher Grant Ward

Markus Gershater

Markus Gershater

Sean Ward

Sean Ward

Founder and CTO

Synthace Office Locations

Synthace has an office in London
London, GB (HQ)
2 Royal College St
Show all (1)
Report incorrect company information

Synthace Financials and Metrics

Summary Metrics

Synthace's latest funding round in September 2017 was reported to be $9.9 m. In total, Synthace has raised $16.2 m

Synthace Financials

Synthace's revenue was reported to be £581 in FY, 2013

Revenue (FY, 2013)


Net income (FY, 2013)

(361.6 k)

EBITDA (FY, 2013)

(356.8 k)

EBIT (FY, 2013)

(361.6 k)

Cash (31-May-2017)

224.3 k
GBPFY, 2012FY, 2013



Operating expense total

362.2 k


(356.8 k)

EBITDA margin, %

GBPFY, 2012FY, 2013

Net Income

(43.1 k)(361.6 k)
GBPY, 2017

Financial Leverage

-1.6 x
Show all financial metrics
Report incorrect company information

Synthace News and Updates

Synthace reels in $9.6 mln Series A

London-based Synthace, the developer of the Antha operating system for biology, has raised $9.6 million in Series A funding. The investors included White Cloud Capital, Amadeus Capital Partners, Eleven Two Capital, Sofinnova Partners, SOSV and Bioeconomy Capital.
Report incorrect company information